Importance: Acute sore throat poses a significant burden on primary care and is a source of inappropriate antibiotic prescribing. Corticosteroids could be an alternative symptomatic treatment.

Objective: To assess the clinical effectiveness of oral corticosteroids for acute sore throat in the absence of antibiotics.

Design, Setting, And Participants: Double-blind, placebo-controlled randomized trial (April 2013-February 2015; 28-day follow-up completed April 2015) conducted in 42 family practices in South and West England, enrolled 576 adults recruited on the day of presentation to primary care with acute sore throat not requiring immediate antibiotic therapy.

Interventions: Single oral dose of 10 mg of dexamethasone (n = 293) or identical placebo (n = 283).

Main Outcomes And Measures: Primary: proportion of participants experiencing complete resolution of symptoms at 24 hours. Secondary: complete resolution at 48 hours, duration of moderately bad symptoms (based on a Likert scale, 0, normal; 6, as bad as it could be), visual analog symptom scales (0-100 mm; 0, no symptom to 100, worst imaginable), health care attendance, days missed from work or education, consumption of delayed antibiotics or other medications, adverse events.

Results: Among 565 eligible participants who were randomized (median age, 34 years [interquartile range, 26.0-45.5 year]; 75.2% women; 100% completed the intervention), 288 received dexamethasone; 277, placebo. At 24 hours, 65 participants (22.6%) in the dexamethasone group and 49 (17.7%) in the placebo group achieved complete resolution of symptoms, for a risk difference of 4.7% (95% CI, -1.8% to 11.2%) and a relative risk of 1.28 (95% CI; 0.92 to 1.78; P = .14). At 24 hours, participants receiving dexamethasone were not more likely than those receiving placebo to have complete symptom resolution. At 48 hours, 102 participants (35.4%) in the dexamethasone group vs 75 (27.1%) in the placebo group achieved complete resolution of symptoms, for a risk difference of 8.7% (95% CI, 1.2% to 16.2%) and a relative risk of 1.31 (95% CI, 1.02 to 1.68; P = .03). This difference also was observed in participants not offered delayed antibiotic prescription, for a risk difference of 10.3% (95% CI, 0.6% to 20.1%) and a relative risk of 1.37 (95% CI, 1.01 to 1.87; P = .046). There were no significant differences in any other secondary outcomes.

Conclusions And Relevance: Among adults presenting to primary care with acute sore throat, a single dose of oral dexamethasone compared with placebo did not increase the proportion of patients with resolution of symptoms at 24 hours. However, there was a significant difference at 48 hours.

Trial Registration: isrctn.org Identifier: ISRCTN17435450.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470351PMC
http://dx.doi.org/10.1001/jama.2017.3417DOI Listing

Publication Analysis

Top Keywords

acute sore
20
sore throat
20
complete resolution
16
resolution symptoms
16
primary care
12
risk difference
12
relative risk
12
oral dexamethasone
8
care acute
8
symptoms hours
8

Similar Publications

Although human metapneumovirus(hMPV) infection can induce severe symptoms in older adults or immunocompromised patients, it usually causes mild symptoms in young immunocompetent adults. The prevalence of hMPV infectious disease is highest during the late winter and early summer. We report a hypoxemic case of hMPV infection in a young immunocompetent man that occurred in the first autumn after the reclassification of coronavirus disease (COVID-19) from Class 2 to Class 5.

View Article and Find Full Text PDF

Clinical characteristics and outcomes of patients with nonrheumatic streptococcal pharyngitis associated myocarditis.

Am J Med

January 2025

Division of Cardiology, Sheba Medical Center, Ramat Gan, Israel; The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Reports of nonrheumatic streptococcal pharyngitis associated myocarditis (SPAM) are rare, and its incidence, pathophysiology, and clinical features remain unclear. We evaluated the clinical course and outcome of patients diagnosed with nonrheumatic SPAM, with a particular focus on differentiating it from other etiologies of myocarditis.

Methods: Seventy-nine consecutive individuals (age 32±9 years, 71 men) with clinically diagnosed SPAM were evaluated.

View Article and Find Full Text PDF

The clinical assessment of lung involvement in patients with Still's disease, results from the multicentre international AIDA Network Still's Disease Registry.

Rheumatology (Oxford)

January 2025

Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.

Objectives: To assess the lung involvement in patients with Still's disease, an inflammatory disease assessing both children and adults. To exploit possible associated factors for parenchymal lung involvement in these patients.

Methods: A multicentre observational study was arranged assessing consecutive patients with Still's disease characterized by the lung involvement among those included in the AIDA (AutoInflammatory Disease Alliance) Network Still's Disease Registry.

View Article and Find Full Text PDF

Background: Illness severity, comorbidity, fever, age and symptom duration influence antibiotic prescribing for respiratory tract infections (RTI). Non-medical determinants, such as patient expectations, also impact prescribing.

Aim: To quantify the effect of general practitioners' (GPs') perception of a patient request for antibiotics on antibiotic prescribing for RTI and investigate effect modification by medical determinants and country.

View Article and Find Full Text PDF

Dysphonia and COVID-19: A Review.

J Voice

January 2025

Ophthalmology, Otorhinolaryngology, and Head and Neck Surgery Department, Universidade Estadual Paulista Julio de Mesquita Filho, Botucatu Medical School, UNESP, São Paulo, Brazil.

Introduction: Vocal symptoms are frequent in patients with coronavirus disease 2019 (COVID-19) and may occur during or after infection.

Objective: To conduct a descriptive review on the topic "dysphonia and COVID-19" in order to alert specialists to these symptoms associated with the virus and sequelae.

Methodology: A literature review was carried out in the main databases: Web of Science, PubMed, Google Scholar, and Scopus, between April 2020 and April 2024 using descriptors that related COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) to voice disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!